Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings demonstrate that IL-17 regulates SHP-2 expression and IL-17RA/STAT-3 dependent production of Cyr61, IL-23, GM-CSF and RANKL in AA-FLS and may reveal a new insight into the pathogenesis of RA.
|
28898718 |
2017 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mavrilimumab, a fully human monoclonal antibody targeting the granulocyte-macrophage colony-stimulating factor receptor-α, was evaluated in patients with moderate-to-severe RA.
|
28213566 |
2017 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pharmacodynamic biomarkers and differential effects of TNF- and GM-CSF-targeting biologics in rheumatoid arthritis.
|
30358109 |
2019 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
CTD_human |
Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population.
|
22446963 |
2012 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cytokines in chronic inflammatory arthritis. IV. Granulocyte/macrophage colony-stimulating factor-mediated induction of class II MHC antigen on human monocytes: a possible role in rheumatoid arthritis.
|
2504878 |
1989 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Evidence for GM-CSF receptor expression in synovial tissue. An analysis by semi-quantitative polymerase chain reaction on rheumatoid arthritis and osteoarthritis synovial biopsies.
|
8049356 |
1994 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In RA, plasma S100A4 correlated with increased CSF2, and increased PRDM8 transcription in RA monocytes was associated with increased plasma CCL5 and IL-6, as well as therapy-resistance.
|
31037071 |
2019 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Conversely, Th17 cells and their effector molecules interleukin 17A (IL-17A), IL-17F, interferon (IFN)γ, tumor necrosis factor (TNF)α, and granulocyte-macrophage colony-stimulating factor (GM-CSF) are implicated in the pathology of rheumatoid arthritis (RA).
|
29254845 |
2018 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
GM-CSF-mediated inflammation has also been implicated in certain types of autoimmune diseases, including rheumatoid arthritis and multiple sclerosis.
|
25803788 |
2015 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study.
|
21613310 |
2011 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study therefore identifies convergent MAPK pathways on Ser345 that are involved in GM-CSF- and TNF-alpha-induced priming of neutrophils and are activated in RA.
|
16778989 |
2006 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Several in vitro and in vivo studies showed that granulocyte-macrophage colony-stimulating factor (GM-CSF), known to be a hematopoietic factor, is also one of the proinflammatory cytokines involved in macrophage activation, crucial for the pathogenic network of RA.
|
28144129 |
2017 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis.
|
29069507 |
2018 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-alpha.
|
2026869 |
1991 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Induction of tumour necrosis factor receptor-expressing macrophages by interleukin-10 and macrophage colony-stimulating factor in rheumatoid arthritis.
|
16859503 |
2006 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The TTP pathway of TNF-alpha and GM-CSF mRNA degradation is a possible novel target for anti-TNF-alpha therapies for rheumatoid arthritis, and also for other conditions proven to respond to anti-TNF-alpha therapy.
|
15535838 |
2004 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TNF and granulocyte macrophage-colony stimulating factor (GM-CSF) have proinflammatory activity and both contribute, for example, to rheumatoid arthritis pathogenesis.
|
29563337 |
2018 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
DC-SIGN expression on RA monocytes or on monocytes stimulated with granulocyte-macrophage colony-stimulating factor and interleukin-4 was further investigated by flow cytometry.
|
12571844 |
2003 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, in the presence of RANKL and macrophage colony-stimulating factor, differentiation and activation of human osteoclasts were also suppressed by DHMEQ, suggesting the possibility of future application of NF-kappaB inhibitors to rheumatoid arthritis therapy.
|
17892600 |
2007 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
RA (n = 7) and healthy control (n = 7) neutrophils were treated with baricitinib or tofacitinib for 30 min, prior to incubation in the absence or presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) or interferon (IFN)-γ. JAKi prevented GM-CSF- and IFN-γ-induced apoptosis delay in RA and healthy control neutrophils in a dose-dependent manner.
|
28369741 |
2017 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Whereas, CM3D was characterised by a prevailing expression of anti-inflammatory cytokines such as IL-10 and LIF, along with trophic factors involved in different mechanisms leading to tissue regeneration, such as PDGF-BB, FGF-2, I-309, SCF, and GM-CSF; CM2D presented relatively higher levels of IL-6, MCP-1, and IL-21, with recognised pro-inflammatory roles in joint disease and pleiotropic effects in the progression of rheumatoid arthritis (RA).
|
30804924 |
2019 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Silencing of NFkappaB1 by small interfering RNA abrogated the capacity of RA bone marrow CD34+ cells to differentiate into fibroblast-like cells and to produce MMP-1 and vascular endothelial growth factor upon stimulation with stem cell factor, granulocyte-macrophage colony stimulating factor and TNF-alpha without influencing their viability and capacity to produce beta2-microglobulin.
|
16519794 |
2006 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
mRNAs encoding RANKL, RANK, OPG and macrophage-colony stimulating factor were expressed by cells isolated from RA joints.
|
11426018 |
2001 |
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Interleukin 1-beta (IL-1 beta), IL-2, IL-4, IL-5, IL-6, IL-8, tumour necrosis factor-alpha (TNF-alpha), transforming growth factor-beta (TGF-beta) and granulocyte-macrophage colony-stimulating factor (GM-CSF) gene expression was determined in knee synovium of 16 patients with rheumatoid arthritis (RA) and 16 patients with seronegative spondyloarthropathies (SSP), by using polymerase chain reaction (PCR) amplification.
|
9117172 |
1997 |
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
This 24-week, phase IIb, double-blind study was undertaken to evaluate the efficacy and safety of mavrilimumab (a monoclonal antibody to granulocyte-macrophage colony-stimulating factor receptor α) and golimumab (a monoclonal antibody to tumor necrosis factor [anti-TNF]) in patients with rheumatoid arthritis (RA) who have had an inadequate response to disease-modifying antirheumatic drugs (DMARDs) (referred to as DMARD-IR) and/or inadequate response to other anti-TNF agents (referred to as anti-TNF-IR).
|
28941039 |
2018 |